AstraZeneca
AstraZeneca’s Imfinzi meets endpoint at Phase 3 interim analysis in extensive-stage small cell lung cancer
June 27, 2019Research and Development AstraZeneca, Imfinzi, pharma
AstraZeneca has lifted the curtain on new Phase 3 data for Imfinzi (durvalumab) in the first-line treatment of extensive-stage small …
EU approval for MSD and AZ’s Lynparza in first-line BRCA-mutated advanced ovarian cancer
June 18, 2019Manufacturing and Production, Sales and Marketing AstraZeneca, Cancer, MSD, lynparza, ovarian cancer, pharma
AstraZeneca and MSD’s jointly-developed therapy Lynparza (olaparib) has scored its third EU approval, the pair announced, with authorisation for the …
AstraZeneca spends more than twice as much as expected on new HQ
June 12, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Cambridge, UK, headquarters, pascal soriot, pharma
AstraZeneca’s new headquarters in Cambridge, United Kingdom are expected to cost more than double the sum of £330 million that …
AstraZeneca’s Phase 3 Farxiga data impresses in type 2 diabetes
June 11, 2019Manufacturing and Production, Research and Development AstraZeneca, diabetes, farxiga, pharma, type 2 diabetes
AstraZeneca has presented new Phase 3 data at the American Diabetes Association (ADA) 79th Scientific Sessions in San Francisco on …
AstraZeneca’s Calquence shows strength in most common adult leukaemia
June 6, 2019Research and Development AstraZeneca, Calquence, chronic lymphocytic leukaemia, pharma
AstraZeneca has unveiled new Phase 3 data for Calquence (acalabrutinib) in treatment-naïve chronic lymphocytic leukaemia, showing that the drug met …
AZ ends Calquence trial early after Phase 3 success in chronic lymphocytic leukaemia
May 8, 2019Research and Development AstraZeneca, Calquence, pharma
AstraZeneca has unveiled new Phase 3 data on the efficacy of its Bruton tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib) in …
AZ and MSD’s Lynparza secures CHMP nod in first-line BRCA-mutated ovarian cancer
April 29, 2019Sales and Marketing AstraZeneca, CHMP, Cancer, MSD, lynparza, ovarian cancer, pharma
AstraZeneca and MSD’s Lynparza (olaparib) has received a positive opinion from the EMA’s Committee for Medicinal Products for Human Use …
Europe approves Lynparza in HER2-, gBRCAm advanced breast cancer
April 10, 2019Research and Development, Sales and Marketing AstraZeneca, Cancer, MSD, breast cancer, lynparza, pharma
Lynparza (olparib), the poly ADP ribose polymerase (PARP) inhibitor developed by AstraZeneca and MSD, has been awarded marketing approval by …
Top Ten most popular articles on Pharmafile.com this week!
April 5, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, AstraZeneca, Northern Ireland, Novartis, Placebo, UK, brexit, pharma
As Brexit looms, pharma trade lobby the ABPI called for a ban on exports of medicines in the case of …
AstraZeneca’s early-stage Fasenra study smashes primary endpoint in hypereosinophilic syndrome
April 4, 2019Research and Development AstraZeneca, Fasenra, hypereosinophilic syndrome, pharma
AstraZeneca has revealed new data for Fasenra (benralizumab), demonstrating that patients using the drug can “achieve near-complete depletion of eosinophils …
AstraZeneca and Daiichi Sankyo partner up for $6.9 billion cancer collaboration
March 29, 2019Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Cancer, Daiichi Sankyo, pharma
AstraZeneca and Daiichi Sankyo have announced a new collaboration agreement to the tune of potentially $6.9 billion which will see …
AstraZeneca’s Imfinzi to be made available via Cancer Drugs Fund in England
March 28, 2019Sales and Marketing AstraZeneca, Cancer, Imfinzi, NHS, NICE, UK, lung cancer
AstraZeneca’s PD-L1 inhibitor Imfinzi (durvalumab) will now be made available to English lung cancer patients on the NHS via the …
AZ’s diabetes drug Forxiga secures EU approval for adjunctive use in type 1 patients
March 25, 2019Sales and Marketing AstraZeneca, Forxiga, diabetes, pharma
AstraZeneca has revealed that its sodium-glucose co-transporter 2 (SGLT2) inhibitor Forxiga (dapagliflozin) has secured approval from the European Commission for …
Top Ten most popular articles on Pharmafile.com this week!
March 22, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Biogen, Eisai, FDA, Merck, NICE, Pfizer, Roche, Sandoz
This week was a bad week for clinical trials. While the FDA put Roche and AbbVie’s multiple myeloma trial on …
AZ’s Farxiga reduces major adverse cardiovascular event risk in type 2 diabetes, new data shows
March 19, 2019Manufacturing and Production, Research and Development AstraZeneca, cardiovascular, farxiga, pharma
AstraZeneca has lifted the curtain on new Phase 3 data for its sodium-glucose co-transporter 2 (SGLT2) inhibitor Farxiga (dapagliflozin), reinforcing …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
